Certain A Shares of Novogene Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-APR-2022.
April 12, 2022
Share
Certain A Shares of Novogene Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-APR-2022. These A Shares will be under lockup for 371 days starting from 7-APR-2021 to 13-APR-2022.
Details:
The companys holding shareholder, actual controller, core technical personnel Li Ruiqiang promised that within 36 months after the listing date, will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares. If the closing price of the companys share is lower than the issue price for 20 consecutive trading days within 6 months after listing, or if the closing price of the companys share is lower than the issue price for the period ending six months after listing, then the lockup period will automatically be extended for 6 months. After the expiry of the lock-up period (including the extended lock-up period), the party promise that yearly transfer of shares made by him/her will not exceed 25% of the holding.
Beijing Nuohe Hegu Investment Management Center (Limited Partnership), Beijing Zhiyuan Hegu Investment Management Center (Limited Partnership) which are controlled by Li Ruiqiang promised that within 36 months after the listing date, will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares.
Individual shareholder Jiang Zhi, other shareholders Advanced Manufacturing Industry Investment Fund (Limited Partnership), Jianchuang Zhongmin (Kunshan) Venture Capital Enterprise (Limited Partnership), Tianjin Haihe Baichuan Equity Investment Fund Enterprise (Limited Partnership), Shenzhen Zhaoshang Zhaoyin Equity Investment Fund Partnership Enterprise (Limited Partnership), Service Trade Innovation Development Guidance Fund (Limited Partnership), Zhongji Capital Management Co., Ltd., Shanghai Fanghe Investment Center (Limited Partnership), Growth No. 12 Investment (Shenzhen) Partnership Enterprise (Limited Partnership) and Shenzhen Zhaoyin Gongying Equity Investment Partnership Enterprise (Limited Partnership), Sequoia Anchen (Xiamen) Equity Investment Partnership Enterprise (Limited Partnership), the companys supervisors promised that within 12 months after the listing date, will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares.
The companys directors, management personnel, core technical personnel Cao Zhisheng, Wang Dawei promised that within 12 months after the listing date, will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares. If the closing price of the companys share is lower than the issue price for 20 consecutive trading days within 6 months after listing, or if the closing price of the companys share is lower than the issue price for the period ending six months after listing, then the lockup period will automatically be extended for 6 months.
Novogene Co Ltd is a China-based company principally engaged in gene sequencing. The Company mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The Company's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The Company conducts its businesses in domestic and overseas markets.